Almac Selected as a National Champion in the 2014/15 European Business Awards
Almac are delighted to be named as a National Champion in the “UKTI Award for Innovation” category in this year’s European Business Awards — a prestigious competition supported by businesses leaders, academics, media and political representatives from across Europe.
The annual award, sponsored by RSM International is now in its eighth year and, with 33 countries represented, is Europe’s largest and most significant cross-sector business recognition programme designed to promote excellence, best practice and innovation.
Alan Armstrong, CEO Almac commented: “We are very proud to be selected as a National Champion representing the UK for Innovation. The European Business Awards is widely recognised as the showcase for Europe’s most dynamic companies and we are delighted to have the opportunity to explain in more depth how we have achieved business success.”
Adrian Tripp, CEO of the European Business Awards said: “Congratulations to Almac, it is a great achievement to be named National Champion. The European Business Awards is going from strength to strength, inspiring businesses to greater success and helping to improve the competitive edge of companies across Europe.”
Jean Stephens, CEO of RSM International, said: “Every year these awards get tougher and more competitive as more companies, of varied sizes and across all sectors, choose to compete in this prestigious competition.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.